• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Hims & Hers Health Inc. (Amendment)

    2/14/24 4:19:29 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email
    SC 13G/A 1 hims13ga.htm



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G
    (Rule 13d-102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO § 240.13d-2.
    (Amendment No. 3)*


    Hims & Hers Health, Inc.
    (Name of Issuer)
     
    Class A Common Stock, $0.0001 par value per share
    (Title of Class of Securities)
     
    433000 106
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     
    ☐
    Rule 13d-1(b)
     
    ☒
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP NO.
    433000 106

     
     
                        See response in row 7.
    1
    NAMES OF REPORTING PERSONS
     
     
     
    Jack Abraham
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ☐  
    (b) ☒ 
    3
    SEC USE ONLY
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    9,324,3961
     
     
    6
    SHARED VOTING POWER
     
     
    7
    SOLE DISPOSITIVE POWER
     
    9,324,3961
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    9,324,3961
     
     
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
      ☐
              
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.6%2
     
     
    12
    TYPE OF REPORTING PERSON*
     
    IN
     
     

    1
    Consists of (i) 68,475 shares of Class A Common Stock held by Atomic Incentives, LLC (“Incentives”), (ii) 319,693 shares of Class A Common Stock held by Atomic Labs I, L.P. (“Labs I”), (iii) 238,967 shares of Class A Common Stock held by Atomic Labs I-B, L.P. (“Labs I-B”), (iv) 4,039,801 shares of Class A Common Stock held by The Jack Abraham Living Trust (“Living Trust”), (v) 2,541,558 shares of Class A Common Stock held by The Jack Abraham 2020 Irrevocable Trust A (“Abraham Trust”), (vi) 55,206 shares of Class A Common Stock held by Atomic GP II, LLC (“Atomic GP II”), (vii) 2,030,303 shares of Class A Common Stock held by Atomic Labs II L.P. (“Labs II”) and (viii) 30,393 shares of Class A Common Stock held by Atomic Labs, LLC (“Labs LLC”). Mr. Abraham is the sole manager of Labs LLC, which is the sole member of Incentives and, as such, may be deemed to hold voting and dispositive power with respect to the securities held by Labs LLC and Incentives. Mr. Abraham is the sole managing member of Atomic Labs GP I, LLC, which is the general partner of Labs I and Labs I-B and, as such, may be deemed to hold voting and dispositive power with respect to the securities held by Labs I and Labs I-B. Mr. Abraham may be deemed to hold voting and dispositive power with respect to the securities held by Living Trust. Mr. Abraham may be deemed to hold voting and dispositive power with respect to the securities held by Abraham Trust. Mr. Abraham is a managing member of Atomic GP II and, as such, may be deemed to hold voting and dispositive power with respect to the securities it holds. Mr. Abraham is a managing member of Atomic GP II, which is the general partner of Labs II and, as such, may be deemed to hold voting and dispositive power with respect to the securities held by Labs II. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities held by entities affiliated with him except to the extent of his indirect pecuniary interest therein, if any.

    2
    The percentage calculation is based on a total of 203,615,885 shares of Class A Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2023.

    CUSIP NO.
    433000 106

     
     
     
    Item 1(a)
    Name of Issuer:
     
     
     
    Hims & Hers Health, Inc. (the “Issuer”)
     
     
    Item 1(b)
    Address of Issuer's Principal Executive Offices:
     
     
     
    2269 Chestnut Street, #523, San Francisco, California 94123
     
     
    Item 2(a)
    Name of Person Filing:
     
     
     
    Jack Abraham
     
     
    Item 2(b)
    Address of Principal Business Office or, if none, Residence:
     
     
     
    c/o Atomic Labs, LLC, 215 NW 24th Street, Suite 400, Miami, FL 33127
     
     
    Item 2(c)  Citizenship:
     
     
    See Row 4 of cover page for the Reporting Person
     

    Item 2(d)
    Title of Class of Securities:
     
     
     
    Class A Common Stock, par value $0.0001 (“Class A Common Stock”)
     
     
    Item 2(e)
    CUSIP No.:
     
     
     
    433000 106
     
     
    Item 3
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:
     
     
     
    Not applicable.
     
     
    Item 4
    Ownership:
     
     
     
    The following information with respect to the ownership of the Class A Common Stock of the Issuer by the person filing this Statement is provided as of December 31, 2023:

     
    (a)
      Amount beneficially owned: See Row 9 of cover page for the Reporting Person.

     
    (b)
      Percent of class:  See Row 11 of cover page for the Reporting Person.
     
     
    (c)
      Number of shares as to which such person has: 
     
     
    (i)
      Sole power to vote or direct the vote:  See Row 5 of cover page for the Reporting Person.
     
     
     
    (ii)
      Shared power to vote or direct the vote: See Row 6 of cover page for the Reporting Person.
     
     
     
    (iii)
      Sole power to dispose or direct the disposition:  See Row 7 of cover page for the Reporting Person.
     
     
     
    (iv)
      Shared power to dispose or direct the disposition: See Row 8 of cover page for the Reporting Person.
     
     

    Item 5
    Ownership of Five Percent or Less of a Class:
     
     
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
     
     
    Item 6
    Ownership of More Than Five Percent on Behalf of Another Person:
     
     
     
    Not applicable.
     
     
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
     
     
     
    Not applicable.
     
     
    Item 8
    Identification and Classification of Members of the Group:
     
     
     
    Not applicable.
     
     
    Item 9
    Notice of Dissolution of Group:
     
     
     
    Not applicable.
     
     
    Item 10
    Certification:
     
     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
     
     
     

    CUSIP NO.
    433000 106

     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule 13G is true, complete and correct.

    Date: February 14, 2024


     

     
     JACK ABRAHAM
     
     
     
     
     
       
     



     
     By:  /s/ Jack Abraham
     



     
     Name:  Jack Abraham
     




    Get the next $HIMS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    6/23/2025Buy → Hold
    Needham
    6/4/2025$61.00 → $65.00Buy
    Needham
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    1/7/2025$35.00Buy
    BTIG Research
    12/17/2024$42.00Overweight
    Morgan Stanley
    11/14/2024Buy → Underperform
    BofA Securities
    More analyst ratings

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hims & Hers Health downgraded by Needham

    Needham downgraded Hims & Hers Health from Buy to Hold

    6/23/25 11:43:05 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Needham reiterated coverage on Hims & Hers Health with a new price target

    Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $65.00 from $61.00 previously

    6/4/25 7:59:55 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health downgraded by TD Cowen with a new price target

    TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00

    4/29/25 8:05:51 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Hims & Hers Health Inc.

    SCHEDULE 13G - Hims & Hers Health, Inc. (0001773751) (Subject)

    8/13/25 12:56:59 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Hims & Hers Health Inc.

    10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)

    8/4/25 4:18:59 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    8/4/25 4:13:03 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

    Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. "It's never been more clear that we are delivering exactly what millions of people have been waiti

    8/4/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Data Shows Personalized GLP-1 Plans Drive Real Weight Loss, Few Side Effects, and Strong Adherence to Care

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today released new data showing that its personalized, digital-first approach to weight loss is driving meaningful, sustainable results, laying the groundwork for lasting success. In a first-of-its-kind U.S. analysis of treatment plans, including compounded GLP-1s, customers taking a compounded GLP-1 reported losing an average of 20.9 pounds or 10.3% of initial body weight, within six months, while reporting a low rate of side effects. Just as importantly, 75% of customers remained on treatment plans in the same timeframe, a powerful signal of real-world trust and clinical success.1 This press

    7/29/25 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Second Quarter 2025 Financial Results on August 4, 2025

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's manageme

    7/14/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Okupe Oluyemi exercised 11,581 shares at a strike of $5.01 and sold $556,420 worth of shares (11,581 units at $48.05), increasing direct ownership by 116% to 116,806 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/15/25 4:18:27 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Legal Officer Boughton Soleil sold $132,818 worth of shares (2,572 units at $51.64), decreasing direct ownership by 2% to 153,021 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/12/25 4:33:50 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Dudum Andrew sold $33,384,120 worth of shares (660,000 units at $50.58) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/11/25 5:07:29 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

    5/8/25 6:50:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

    Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

    5/5/25 9:01:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Define Ventures Appoints Carolyn Magill as Venture Partner

    The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

    3/11/25 5:30:00 AM ET
    $EVH
    $HIMS
    $LVGO
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

    Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. "It's never been more clear that we are delivering exactly what millions of people have been waiti

    8/4/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Second Quarter 2025 Financial Results on August 4, 2025

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's manageme

    7/14/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

    Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.him

    5/5/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care